Search results
Showing 16 to 30 of 63 results for tuberculosis
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.
What effects does isolation have on the quality of life of people being treated for TB?
effects does isolation have on the quality of life of people being treated for TB? Any explanatory notes(if applicable) Why this is...
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
Recommendation ID NG33/1 Question In people with suspected TB, what is the relative clinical and cost effectiveness of universal...
NICE research projects and partners.
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
ID NG33/5 Question For people with active, drug susceptible TB who experience treatment interruptions because of adverse events,...
from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa)....
Adalimumab for the treatment of adults with psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
Infliximab for the treatment of adults with psoriasis (TA134)
Evidence-based recommendations on infliximab for treating severe psoriasis in adults.
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.